Coloplast : Q4 review – Good quarter, bottom line guidance implies slight downside
>Q4 review – Slight beat on top and bottom line - Coloplast’s Q4 2024 revenues of DKK 6,983m (+11.7% y-o-y) were 0%/1% vs ODDO BHF/consensus, driven by organic growth of 8% (7.7%/8.0% vs ODDO BHF/consensus). External growth contributed to the tune of 4% and forex created a headwind of 100bp. Coloplast achieved an adj. EBIT of DKK 1,913m (+16.3% y-o-y, margin 27.5%), which was 2%/2% vs expectations. EPS of DKK 5.83 compares to our DKK 6.52 and consensus’ DKK 6.00....Coloplast is a supplier of intimate healthcare products and services. Co. develops and markets products that support people with diseases of a private nature. Co. operates in three business areas: Ostomy care, products for people whose intestinal outlet has been rerouted through the abdominal wall; Urology and continence care products, for people suffering from diseases of the kidneys, the urinary system and the male reproductive system; Dressings, for the treatment of chronic wounds and skin care products for prevention and treatment. Co. markets and sells its products and services globally. Co. supplies products to hospitals, institutions as well as wholesalers and retailers.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.